February 2022—Biodesix announced the launch of its GeneStrat NGS genomic test, a blood-based tumor profiling test. The 52-gene panel includes guideline-recommended mutations to help physicians treating advanced-stage lung cancer patients identify targeted therapy mutations, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others.
Read More »Biodesix launches GeneStrat NGS, IQLung testing strategy
Jan. 28, 2022—Biodesix announced the launch of its GeneStrat NGS genomic test, a blood-based tumor profiling test.
Read More »Biodesix partners with Streck
March 2020—Biodesix and Streck announced a regulatory cooperation agreement that will further enable the companies to pursue FDA approval for diagnostic testing services and specimen collection products.
Read More »Blood specimen collection device
January 2020—Biodesix announced it has been issued a patent for its Biodesix Collection Device. The device aims to improve ease of use in blood sample collection for diagnostic testing. The BCD, which is currently used with the Biodesix Nodify XL2 test, combines multiple sample processing steps, including specimen collection and reproducible sample separation with ambient shipping. The company plans to use the BCD in all proteomic testing and make the device available for purchase by labs and diagnostic companies for sample processing and testing.
Read More »Biodesix to acquire Oncimmune lab
October 2019—Biodesix (Boulder, Colo.) announced that it will acquire Oncimmune’s U.S. operations, which include a CLIA lab in De Soto, Kan., and the company’s incidental pulmonary nodule malignancy test, Early-CDT Lung.
Read More »ROS1, RET mutations added to liquid biopsy test, 5/17
May 2017—Biodesix announced that its GeneStrat test, a liquid biopsy for patients with cancer, now includes ROS1 and RET. GeneStrat is a noninvasive blood test analyzing circulating tumor DNA and RNA. The test provides highly sensitive results in 72 hours for non-small cell lung cancer patients.
Read More »Targeted liquid biopsy mutation test, 7/15
July 2015—Biodesix launched GeneStrat, a targeted liquid biopsy mutation test for genotyping tumors of patients with advanced non-small cell lung cancer. Requiring only a blood draw, the test aims to offer a fast, minimally invasive alternative to a high-risk tissue biopsy or re-biopsy in patients with insufficient tissue.
Read More »Study published on VeriStrat proteomic test, 7/15
July 2015—The journal Lung Cancer published a paper demonstrating the economic implications to the U.S. health care system of using VeriStrat in guiding treatment of patients with advanced non-small cell lung cancer. The paper’s authors conclude that using Biodesix’s VeriStrat improves overall survival and decreases medical costs in the U.S. payer system.
Read More »